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A New Era in the Pharmacological
Management of Atrial Fibrillation
Atrial ﬁbrillation (AF) is the most prevalent sustained cardiac arrhythmia in clinical
practice. It is important to know how and when to treat this troublesome arrhythmia with
antiarrhythmic drugs. The attitudes of physicians have changed since clinical trials such as
AFFIRM and RACE, which showed that ventricular rate control was not inferior to rhythm
control in patients with AF, were reported in 2002. For a long time, many arrhythmologists
have been considering how to prevent recurrence of this troublesome arrhythmia.
For patients with symptomatic paroxysmal AF, looking back over the last ten years, the
‘‘pill-in-the-pocket’’ approach using potent class I drugs such as ﬂecainide, propafenone
or pilsicainide is still frequently resorted to in an outpatient setting. The frequency
of prescription of antiarrhythmic drugs for prevention of the recurrence of AF has now
declined somewhat, and much attention has turned to up-stream therapy such as ACE-I,
ARB, and statins for fundamental treatment.
At present, the main direction of AF management has shifted to how to manage
the underlying substrate of AF that perpetuates this arrhythmia and the occurrence of
thromboembolism. One of the most important aspects is the inﬂammation process which
may contribute to the development of the AF substrate in the left atrium. Many reports
recognize the contribution of inﬂammation in the left atrium as an underlying process in
AF. In clinical practice, in fact, control of blood pressure and improvement of left
ventricular function cause reduction of left atrial overload, and may yield favorable
outcomes. Valsaltan and irbesartan unfortunately did not bring about any suppression of
AF recurrence. More than half of the subjects in these clinical trials were pretreated with
ACE-I, and so the primary outcome shows no signiﬁcant diﬀerence. At present, the
prevention of thromboembolism is the most important objective in AF patients. For this
purpose, the vitamin K antagonist warfarin was the sole oral formula whose action
in clinical use is characterized by slow onset of action and slow elimination. This year,
the novel anticoagulant dabigatran was released onto the market for clinical use. The
advantages of this direct thrombin inhibitor are: ﬁrstly, ﬁxed dose without any monitoring,
which could oﬀer satisfactory clinical eﬀects superior to those of an adjusted dose
of warfarin; and secondly, the clinical eﬀect is not aﬀected by food intake or by co-
medication. This can be considered as the beginning of a new era, and the best strategy
for each AF patient must be chosen carefully. In the case of rhythm control, non-
pharmacological treatment should be chosen at an early stage as a ﬁrst-line treatment.
Pharmacotherapy may still be able to contribute to the management of AF patients, but the
choice of an antiarrhythmic drug may reduce the frequency and shorten the duration of the
treatment. It will be necessary to seek further appropriate strategies in the future for the
treatment of AF patients.
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